Trial Profile
A phase 1 study of cisplatin/pemetrexed/crizotinib followed by maintenance crizotinib in patients with stage 3B or 4 EML4-ALK positive non-small-cell lung cancer.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 06 Dec 2012 New trial record